Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.49 |
| ▸ | PRSS12 | P56730 | 5/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
| ▸ | FOXO1 | Q12778 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650908 | 0.94 | FOXO1 (0.43) | RHEBPRSS12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5651818 | 0.93 | FOXO1 (0.42) | RHEBPRSS12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5648605 | 0.90 | RHEB (0.45) | RHEBPRSS12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5653237 | 0.89 | HDAC6 (0.46) | PRKAG1PRKAA1PRKAB1FOXO1HDAC6 | |
| SCHEMBL5650683 | 0.87 | RHEB (0.47) | RHEBPRSS12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5652259 | 0.85 | PRSS12 (0.47) | RHEBPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5650995 | 0.85 | PRSS12 (0.47) | RHEBPRSS12HDAC6CNR1CNR2 | |
| SCHEMBL5650184 | 0.84 | HPSE (0.45) | RHEBPRSS12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5651558 | 0.84 | HDAC6 (0.45) | FOXO1HDAC6PDE7A | |
| SCHEMBL5652578 | 0.83 | SIRT2 (0.42) | RHEBPRSS12PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | RHEB 946/4885PRSS12 979/4885PRKAG1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.